期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

三阴性乳腺癌的生物学特点和治疗进展 被引量：4

原文传递
导出
摘要 乳腺癌是女性最常见的恶性肿瘤之一。在欧美国家，乳腺癌发病率居女性癌瘤的首位。三阴性乳腺癌（triple-negative breast cancer，TNBC）是指雌激素受体（ER）、孕激素受体（PR）、人类表皮生长因子受体2（HER2）均为阴性的乳腺癌类型，约占乳腺癌的15％。由于其侵袭性强、预后差、缺乏有效治疗成为近几年研究的热点。本文就其生物学特点和近年来的治疗进展做一综述。
作者 高运宾 冀学宁
机构地区 贵州省遵义医学院研究生学院 大连大学附属中山医院肿瘤一科
出处 《中国临床研究》 CAS 2012年第5期417-419,共3页 Chinese Journal of Clinical Research
关键词 乳腺癌 三阴性 雌激素受体 孕激素受体 人类表皮生长因子受体2
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献28

  • 1Perou CM, SФbrlie T, Eisen MB, et al. Molecular portraits of human breast tumours [ J ]. Nature,2000,406 ( 6797 ) : 747 - 752.
  • 2lsmail-Khan R, Bui MM. A review of triple-negative breast cancer [ J ]. Cancer Control,2010,17 ( 3 ) : 173 - 176.
  • 3Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer [J]. N Engl J Med 2009,360(8) :790 -800.
  • 4Rakha EA, Elsheikh SE, Aleskandarany MA, et al. Triple - negative breast cancer: distinguishing between basal and nonbasal subtypes [ J ]. Clin Cancer Res,2009,15 ( 7 ) : 2302 - 2310.
  • 5Santana-Davila R, Perez EA. Treatment options for patients with triple-negative breast cancer[ J]. J Hematol Oncol,2010,3:42.
  • 6Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dosedense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741 [J]. J Clin Oncol,2003,21 (8) : 1431 - 1439.
  • 7Torrisi R, Balduzzi A, Ghlsini R, et al. Tailored preoperative treatment of locally advanced triple negative ( hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and iIffusional fluorouracil followed by weekly paciitaxel [ J ]. Cancer Chemother Pharmaco1,2008,62 (4) :667 - 672.
  • 8Isakoff SJ. Triple-negative breast cancer : role of specific chemotherapy agents[J]. Cancer J,2010,16 ( 1 ) :53 - 61.
  • 9Sirohi B, Arnedos M, Popat S, et al. Platinum-based chemotherapy in triple-negative breast cancer [ J]. Ann Oncol, 2008, 19 ( 11 ) : 1847 - 1852.
  • 10Kavallaris M. Microtubules and resistance to tubulin-binding agents [J]. Nat Rev Cancer,2010,10(3) :194 -204.

同被引文献35

  • 1刘红,荀培,陈可欣,李海欣,郝希山.天津市近20年女性乳腺癌患者临床病理特点及预后变化趋势分析[J].中华医学杂志,2007,87(34):2405-2407. 被引量：13
  • 2Blackstein M, Vogel CL, Ambinder R, et al. Gemcitabine as firsf-line therapy in patients with metastatic breast cancer: a phase IT trail [J]. Oncoloyg,2002,62( 1 ) :2 -8.
  • 3Brodowicz T, Kostler WJ, Moslinger R, el al. Single - agent gemcitabine as second-line and third-line treatment in metastatic breast cancer[ J ]. Breast,2009,9 (6) :338 - 342.
  • 4Tripathy D. Overview: gemcitabine as single-agent therapy for advanced breast cancer[J]. Clin Breast Cancer,2002,3 SuppI 1:8 -11.
  • 5Lose F, Duffy DL, Kay GF, et al. Skewed X chromosome inactivation and breast and ovarian cancer status:evidence for x-linked modifiers of BRCA1 [J]. J Natl Cancer Inst,2008,100(21 ) :1519 - 1529.
  • 6Narod SA. BRCA mutations in the management of breast cancer:The state of the art[J]. Nat Rev Clin Oncol,2010,7(12) :702 -707.
  • 7Staudacher L, Cottu PH, Di6ras V, et al. Platinum-based chemotherapy in metastatic triple-negative breast cancer:the Institut Curie experience [ J ]. Ann Onco1,2011,22 (4) :848 - 856.
  • 8Lee EY. Promotion of BRCA1 -associated tripe-negative breast cancer by ovarian hormones [ J ]. Curt Opin Obstet Gynecol, 2008,20 (1) : 68 - 73.
  • 9Michaud LB. Treatment experienced breast cancer[J]. Am J Health Syst Pharm, 2008, 65(10): 4-9.
  • 10Silver D P,Richardson A L,Eklund A C,et al.Efficacy of neoadjuvant cisplatin in triple-negative breast cancer[J].J Clin Oncol,2010,28(7):1 145-1 153.

引证文献4

二级引证文献20

中国临床研究
2012年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部